Global burden of lung cancer in 2022 and projected burden in 2050

肺癌 医学 入射(几何) 癌症 死亡率 人口学 中国 死因 内科学 疾病 地理 物理 考古 社会学 光学
作者
Lanwei Guo,Chenxin Zhu,Lin Cai,Xinglong Zhang,Yi Fang,Hongda Chen,Haiyan Yang
出处
期刊:Chinese Medical Journal [Lippincott Williams & Wilkins]
标识
DOI:10.1097/cm9.0000000000003268
摘要

Abstract Background: Lung cancer is the most common cancer and a leading cause of cancer-related deaths globally. The aim of this study was to evaluate the incidence and mortality of lung cancer worldwide in 2022 and to project the number of new cases and deaths due to lung cancer in China and the United States in 2050. Methods: In this study, data from the GLOBCAN 2022 database were used to analyze lung cancer incidence and mortality. The current status of lung cancer incidence and deaths was described by country/region, sex, age, and the human development index (HDI), and future lung cancer incidence and deaths in China and the United States were projected for 2050. Results: Globally, an estimated 2,480,675 new lung cancer cases and 1,817,469 lung cancer-related deaths occurred in 2022, with age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) of 23.6/100,000 and 16.8/100,000, respectively. In China, the ASIR and ASMR for male lung cancer patients were approximately 1.7 times and 2.7 times greater than those for female lung cancer patients, respectively. The ASIR and ASMR in high-HDI countries were approximately 8.5 times and 6.5 times those in low-HDI countries, respectively. It is estimated that in 2050, there will be approximately 1120 thousand new cases and 960 thousand deaths among Chinese men, 680 thousand new cases and 450 thousand deaths among Chinese women, approximately 170 thousand new cases and 110 thousand deaths among American men, and 160 thousand new cases and 90 thousand deaths among American women. Conclusions: There are significant differences in the incidence and mortality of lung cancer among different regions and sexes. Therefore, sex factors need to be considered in the prevention, screening, and treatment strategies of lung cancer, and the implementation of tertiary prevention measures for lung cancer, especially primary and secondary prevention, needs to be actively promoted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
端庄栾完成签到,获得积分10
1秒前
1秒前
xhnmdl完成签到 ,获得积分10
1秒前
2秒前
小猫无极发布了新的文献求助10
2秒前
Ying发布了新的文献求助10
2秒前
化学天空完成签到,获得积分10
3秒前
5秒前
听话的梦之完成签到,获得积分10
5秒前
黄黄发布了新的文献求助80
5秒前
7秒前
7秒前
打打应助Chroninus采纳,获得10
7秒前
7秒前
酷酷夜阑完成签到,获得积分10
8秒前
8秒前
风儿完成签到,获得积分10
9秒前
勤能补拙完成签到 ,获得积分10
9秒前
9秒前
gfreezer发布了新的文献求助10
10秒前
10秒前
siwen完成签到,获得积分10
11秒前
Ying完成签到,获得积分20
11秒前
铜锣烧发布了新的文献求助10
12秒前
整齐路灯发布了新的文献求助20
12秒前
12秒前
研途牛马发布了新的文献求助10
12秒前
华仔应助宵宫采纳,获得10
12秒前
难过白易完成签到,获得积分10
12秒前
搜集达人应助现代星月采纳,获得10
12秒前
2799发布了新的文献求助10
13秒前
13秒前
xin_ok完成签到,获得积分20
14秒前
chen完成签到 ,获得积分10
15秒前
科研通AI5应助沙绮晴采纳,获得10
15秒前
yzy完成签到,获得积分10
15秒前
SciGPT应助fireking_sid采纳,获得10
15秒前
SYLH应助xhnmdl采纳,获得10
15秒前
Owen应助astalavista采纳,获得10
16秒前
高分求助中
Разработка метода ускоренного контроля качества электрохромных устройств 500
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 500
Arthur Ewert: A Life for the Comintern 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi // Kurt Werner Radtke 500
Two Years in Peking 1965-1966: Book 1: Living and Teaching in Mao's China // Reginald Hunt 500
Epigenetic Drug Discovery 500
Hardness Tests and Hardness Number Conversions 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3817454
求助须知:如何正确求助?哪些是违规求助? 3360792
关于积分的说明 10409392
捐赠科研通 3078887
什么是DOI,文献DOI怎么找? 1690844
邀请新用户注册赠送积分活动 814169
科研通“疑难数据库(出版商)”最低求助积分说明 768060